[go: up one dir, main page]

BR9711444A - Derivados de adenosina substituìdos por heterocìclico n6. - Google Patents

Derivados de adenosina substituìdos por heterocìclico n6.

Info

Publication number
BR9711444A
BR9711444A BR9711444-8A BR9711444A BR9711444A BR 9711444 A BR9711444 A BR 9711444A BR 9711444 A BR9711444 A BR 9711444A BR 9711444 A BR9711444 A BR 9711444A
Authority
BR
Brazil
Prior art keywords
adenosine derivatives
heterocyclic
adenosine
derivatives replaced
replaced
Prior art date
Application number
BR9711444-8A
Other languages
English (en)
Inventor
Robert T Lum
Jurg R Pfister
Steven R Schow
Michael M Wick
Marek G Nelson
George F Schreiner
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of BR9711444A publication Critical patent/BR9711444A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<B>DERIVADOS DE ADENOSINA SUBSTITUìDOS POR HETEROCìCLICO N^ 6^. A presente invenção abrange derivados de adenosina substituídos por N^ 6^-oxa, tia, tioxa e azacicloalquila, substituídos de forma ideal (I), que são agonistas receptores de adenosina tipo 1, seletivos, e como tal, são agentes potencialmente úteis pra o tratamento de doenças cardiovasculares e distúrbios do sistema nervoso central.
BR9711444-8A 1996-08-27 1997-08-20 Derivados de adenosina substituìdos por heterocìclico n6. BR9711444A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08702234 US5789416B1 (en) 1996-08-27 1996-08-27 N6 mono heterocyclic substituted adenosine derivatives
PCT/US1997/014724 WO1998008855A2 (en) 1996-08-27 1997-08-20 N6 heterocyclic substituted adenosine derivatives

Publications (1)

Publication Number Publication Date
BR9711444A true BR9711444A (pt) 2000-01-18

Family

ID=24820367

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711444-8A BR9711444A (pt) 1996-08-27 1997-08-20 Derivados de adenosina substituìdos por heterocìclico n6.

Country Status (24)

Country Link
US (1) US5789416B1 (pt)
EP (3) EP0920438B1 (pt)
JP (1) JP3157842B2 (pt)
KR (1) KR100331775B1 (pt)
CN (1) CN100363377C (pt)
AT (2) ATE202361T1 (pt)
AU (1) AU726597B2 (pt)
BR (1) BR9711444A (pt)
CA (1) CA2264155C (pt)
CZ (1) CZ296855B6 (pt)
DE (2) DE69719816T2 (pt)
DK (2) DK0992510T3 (pt)
ES (2) ES2157593T3 (pt)
GE (1) GEP20012419B (pt)
GR (1) GR3036332T3 (pt)
HU (1) HU226057B1 (pt)
IL (2) IL128652A0 (pt)
NO (3) NO312679B1 (pt)
NZ (3) NZ334095A (pt)
PL (1) PL187635B1 (pt)
PT (1) PT920438E (pt)
TR (2) TR199900377T2 (pt)
UA (1) UA62936C2 (pt)
WO (1) WO1998008855A2 (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
JP2003501431A (ja) * 1999-05-25 2003-01-14 ザ ペン ステート リサーチ ファウンデイション Ｄｎａメチル基転移酵素阻害剤
EP1420021A1 (en) * 1999-05-25 2004-05-19 The Penn State Research Foundation DNA Methyltransferase inhibitors
US6180615B1 (en) * 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6784165B1 (en) 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
ES2215146T3 (es) * 2000-09-08 2004-10-01 Cv Therapeutics, Inc. Utilizacion de ribosidos purina como antiarritmicos.
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20050227933A1 (en) * 2001-11-29 2005-10-13 Benkovic Stephen J Treatment of bacterial induced diseases using DNA methyl transferase inhibitors
US7405304B2 (en) * 2002-01-10 2008-07-29 The Penn State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids
KR20040084929A (ko) 2002-02-19 2004-10-06 씨브이 쎄러퓨틱스, 인코포레이티드 부분적이거나 완전한 ａ1 아데노신 수용체의 작용제
AU2003235466C1 (en) * 2002-04-18 2008-03-20 Gilead Palo Alto, Inc. Method for treating arrhythmias
JP2006502974A (ja) 2002-05-17 2006-01-26 ニューロジェン コーポレイション 置換環縮合イミダゾール誘導体：ｇａｂａａ受容体リガンド
US7163928B2 (en) * 2003-02-03 2007-01-16 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7834014B2 (en) 2003-04-09 2010-11-16 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
CA2523746A1 (en) * 2003-04-24 2004-11-25 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
WO2005025545A2 (en) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Pharmaceutical formulation for controlled release of selodenoson
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US6881851B1 (en) * 2004-04-21 2005-04-19 Eastman Chemical Company Preparation of tetrahydro-3-furoic acid
EP2221307A1 (en) * 2004-05-26 2010-08-25 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
NZ554506A (en) * 2004-09-20 2011-01-28 Inotek Pharmaceuticals Corp Purine derivatives and methods of use thereof
CN100451010C (zh) * 2004-12-21 2009-01-14 厦门大学 一种合成(r)-3-氨基四氢呋喃的方法
WO2006125190A1 (en) * 2005-05-19 2006-11-23 Cv Therapeutics, Inc. A1 adenosine receptor agonists
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
CN100344768C (zh) * 2005-11-24 2007-10-24 东华大学 一种3－(s)－氨基四氢呋喃的酶法合成方法
US7732424B2 (en) * 2005-11-30 2010-06-08 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
CN102016036B (zh) 2008-02-11 2015-04-08 阿克赛医药公司 经修饰的RNAi多核苷酸及其用途
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
CA2743981C (en) 2008-09-22 2019-01-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
SI2523669T1 (sl) 2010-01-11 2017-05-31 Inotek Pharmaceuticals Corporation Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka
US9080171B2 (en) 2010-03-24 2015-07-14 RXi Parmaceuticals Corporation Reduced size self-delivering RNAi compounds
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
WO2011119871A1 (en) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Rna interference in ocular indications
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
SG11201403979TA (en) 2012-01-26 2014-08-28 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
KR20160110370A (ko) 2013-12-04 2016-09-21 알엑스아이 파마슈티칼스 코포레이션 화학적으로 변형된 올리고뉴클레오티드를 사용한 상처 치유의 치료 방법
EP3137119B1 (en) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Methods for treating cancer using a nucleic acid targeting mdm2
WO2015168605A1 (en) 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
KR20180026739A (ko) 2015-07-06 2018-03-13 알엑스아이 파마슈티칼스 코포레이션 슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
CN105218490B (zh) * 2015-11-10 2017-05-03 山东川成医药股份有限公司 一种（r）‑3‑氨基四氢呋喃的制备方法
WO2018195355A1 (en) 2017-04-19 2018-10-25 Rxi Pharmaceuticals Corporation Topical delivery of nucleic acid compounds
US20230002766A1 (en) 2019-11-08 2023-01-05 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides targeting bromodomain containing protein 4 (brd4) for immunotherapy
WO2021138537A1 (en) 2019-12-31 2021-07-08 Phio Pharmaceuticals Corp. Chemically modified oligonucleotides with improved systemic delivery
WO2023015264A1 (en) 2021-08-04 2023-02-09 Phio Pharmaceuticals Corp. Immunotherapy of cancer utilizing natural killer cells treated with chemically modified oligonucleotides
KR20240041973A (ko) 2021-08-04 2024-04-01 피오 파마슈티칼스 코프. 화학적으로 변형된 올리고뉴클레오티드

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460929A1 (de) * 1974-12-21 1976-06-24 Boehringer Sohn Ingelheim Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
JPS57171998A (en) * 1981-04-15 1982-10-22 Fujisawa Pharmaceut Co Ltd Adenosine derivative and its salt, preparation thereof and medicinal composition containing the same
DE3138397A1 (de) * 1981-09-26 1983-04-07 Hoechst Ag, 6230 Frankfurt "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen"
AU577743B2 (en) * 1984-10-26 1988-09-29 Warner-Lambert Company N6-benzopyrano and benzothiopyrano adenosines
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US4954504A (en) * 1986-11-14 1990-09-04 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US4980379A (en) * 1988-06-30 1990-12-25 The University Of Virginia Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
AU626983B2 (en) * 1989-01-31 1992-08-13 Whitby Research, Inc. N6-substituted 9-methyladenines
US5155098A (en) * 1989-06-09 1992-10-13 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines, and pharmaceutical compositions and methods employing them
US5017578A (en) * 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5432164A (en) * 1991-10-24 1995-07-11 Novo Nordisk A/S C2,N6 -disubstituted adenosine derivatives
DE4205306B4 (de) * 1992-02-21 2005-11-24 Glüsenkamp, Karl-Heinz, Dr. Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
EP0704215A3 (en) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer

Also Published As

Publication number Publication date
DE69705312T2 (de) 2001-10-11
ES2157593T3 (es) 2001-08-16
DE69719816T2 (de) 2003-12-18
IL128652A (en) 2008-06-05
ES2189330T3 (es) 2003-07-01
CA2264155A1 (en) 1998-03-05
NZ334095A (en) 2000-10-27
TR200202287T2 (tr) 2003-01-21
KR100331775B1 (ko) 2002-04-09
WO1998008855A3 (en) 1998-09-03
PL187635B1 (pl) 2004-08-31
PT920438E (pt) 2001-10-30
NO990787L (no) 1999-02-19
NO20020758D0 (no) 2002-02-15
EP1081155A3 (en) 2003-05-02
DK0992510T3 (da) 2003-07-07
CZ296855B6 (cs) 2006-07-12
GEP20012419B (en) 2001-04-25
NO20020759L (no) 1999-02-19
WO1998008855A2 (en) 1998-03-05
ATE202361T1 (de) 2001-07-15
CZ61499A3 (cs) 1999-10-13
CA2264155C (en) 2003-11-18
AU726597B2 (en) 2000-11-16
HU226057B1 (en) 2008-04-28
EP0992510A1 (en) 2000-04-12
US5789416A (en) 1998-08-04
CN1234803A (zh) 1999-11-10
KR20000035867A (ko) 2000-06-26
UA62936C2 (en) 2004-01-15
NO990787D0 (no) 1999-02-19
HK1020967A1 (en) 2000-05-26
GR3036332T3 (en) 2001-11-30
EP0920438B1 (en) 2001-06-20
DE69705312D1 (de) 2001-07-26
NO20020758L (no) 1999-02-19
HUP0001640A2 (hu) 2001-05-28
NO20020759D0 (no) 2002-02-15
ATE234323T1 (de) 2003-03-15
NZ512242A (en) 2004-01-30
CN100363377C (zh) 2008-01-23
NO322459B1 (no) 2006-10-09
TR199900377T2 (xx) 1999-05-21
NZ505428A (en) 2005-03-24
EP0920438A2 (en) 1999-06-09
HUP0001640A3 (en) 2002-04-29
EP0992510B1 (en) 2003-03-12
NO312679B1 (no) 2002-06-17
EP1081155A2 (en) 2001-03-07
JP3157842B2 (ja) 2001-04-16
PL331853A1 (en) 1999-08-16
DK0920438T3 (da) 2001-09-10
IL128652A0 (en) 2000-01-31
DE69719816D1 (de) 2003-04-17
US5789416B1 (en) 1999-10-05
AU4080997A (en) 1998-03-19
JP2000501426A (ja) 2000-02-08

Similar Documents

Publication Publication Date Title
BR9711444A (pt) Derivados de adenosina substituìdos por heterocìclico n6.
BR0015962A (pt) Compostos tendo ligações multiplas que são agonistas de receptor adrenérgico (beta)2 úteis no tratamento e prevenção de doenças respiratórias
ES2191769T3 (es) Derivados 3-espiro-indolin-2-ona como ligandos de los receptores de la vasopresina y/o de la ocitocina.
PE14199A1 (es) Agonistas de 5-ht1f
BRPI0413922A (pt) xantinas de 8-heteroarila substituìda
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
BRPI0412843A (pt) lactamas substituìdas e uso das mesmas como agentes anticáncer
FI905957A0 (fi) Foerfarande foer framstaellning av substituerade cyklohexener, som verkar pao det centrala nervsystemet.
BR9814188A (pt) &#34;agonistas de 5-ht1f&#34;
SE9604582D0 (sv) Novel compounds
BR9807312A (pt) Derivados de (4-piperidinil)-1h-2-benzopirano úteis como agentes antipsicóticos
NO20051663L (no) Fremgangsmater for behandling av neurodegenerasjon
BRPI0408899A (pt) compostos benzo[1,2,5]tiadiazol
DK1223930T3 (da) Behandling af dyskinesi
BR0317228A (pt) Inibidores de aminocianopiridina tricìclicos de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
BR9812254A (pt) Gene polimórfico cag de repetição contida e seus usos
BR9912839A (pt) Derivados de piperazinomas e suas aplicações
ES2183843T3 (es) Compuestos triciclicos que tienen afinidad por el receptor 5-ht1a.
BR9803717A (pt) ácidos indol-2-carbocìlicos substituìdos como inibidores de glucosil transferase.
SE9603726D0 (sv) Novel compounds
ES2173027A2 (es) Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time